BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30674530)

  • 1.
    Beckmann PJ; Larson JD; Larsson AT; Ostergaard JP; Wagner S; Rahrmann EP; Shamsan GA; Otto GM; Williams RL; Wang J; Lee C; Tschida BR; Das P; Dubuc AM; Moriarity BS; Picard D; Wu X; Rodriguez FJ; Rosemarie Q; Krebs RD; Molan AM; Demer AM; Frees MM; Rizzardi AE; Schmechel SC; Eberhart CG; Jenkins RB; Wechsler-Reya RJ; Odde DJ; Huang A; Taylor MD; Sarver AL; Largaespada DA
    Cancer Res; 2019 Mar; 79(5):905-917. PubMed ID: 30674530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.
    Larson JD; Largaespada DA
    In Vivo; 2012; 26(4):487-500. PubMed ID: 22773561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of medulloblastomas and related primitive neuroectodermal tumors. A review.
    Fung KM; Trojanowski JQ
    J Neuropathol Exp Neurol; 1995 May; 54(3):285-96. PubMed ID: 7745427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
    Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
    Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background.
    Poh B; Koso H; Momota H; Komori T; Suzuki Y; Yoshida N; Ino Y; Todo T; Watanabe S
    Neuro Oncol; 2019 Aug; 21(8):993-1004. PubMed ID: 30976792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of FoxR2 as an oncogene in medulloblastoma.
    Koso H; Tsuhako A; Lyons E; Ward JM; Rust AG; Adams DJ; Jenkins NA; Copeland NG; Watanabe S
    Cancer Res; 2014 Apr; 74(8):2351-61. PubMed ID: 24599127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood.
    Trojanowski JQ; Fung KM; Rorke LB; Tohyama T; Yachnis AT; Lee VM
    Mol Chem Neuropathol; 1994; 21(2-3):219-39. PubMed ID: 8086035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embryonal tumors in the WHO CNS5 classification: A Review.
    Gianno F; Miele E; Antonelli M; Giangaspero F
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S73-S82. PubMed ID: 35562137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).
    Rogers HA; Miller S; Lowe J; Brundler MA; Coyle B; Grundy RG
    Br J Cancer; 2009 Apr; 100(8):1292-302. PubMed ID: 19293793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.
    Biegel JA; Janss AJ; Raffel C; Sutton L; Rorke LB; Harper JM; Phillips PC
    Clin Cancer Res; 1997 Mar; 3(3):473-8. PubMed ID: 9815707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017.
    Niehusmann P; Stensvold E; Leske H; Pietsch T; Goschzik T; Gielen GH; Due-Tønnessen B; Frič R; Nilssen Y; Brandal P
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29736. PubMed ID: 35570402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of five new cell lines derived from human primitive neuroectodermal tumors of the central nervous system.
    Pietsch T; Scharmann T; Fonatsch C; Schmidt D; Ockler R; Freihoff D; Albrecht S; Wiestler OD; Zeltzer P; Riehm H
    Cancer Res; 1994 Jun; 54(12):3278-87. PubMed ID: 8205550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
    Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
    Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
    Chang Q; Ng HK
    Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):24-8. PubMed ID: 17374234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon.
    Frühwald MC; O'Dorisio MS; Rush LJ; Reiter JL; Smiraglia DJ; Wenger G; Costello JF; White PS; Krahe R; Brodeur GM; Plass C
    J Med Genet; 2000 Jul; 37(7):501-9. PubMed ID: 10882752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor Cells.
    Modzelewska K; Boer EF; Mosbruger TL; Picard D; Anderson D; Miles RR; Kroll M; Oslund W; Pysher TJ; Schiffman JD; Jensen R; Jette CA; Huang A; Stewart RA
    Cell Rep; 2016 Oct; 17(5):1255-1264. PubMed ID: 27783941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
    Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
    PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional genomics identifies drivers of medulloblastoma dissemination.
    Mumert M; Dubuc A; Wu X; Northcott PA; Chin SS; Pedone CA; Taylor MD; Fults DW
    Cancer Res; 2012 Oct; 72(19):4944-53. PubMed ID: 22875024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain and Spinal Cord Tumors of Embryonic Origin.
    Lampros M; Alexiou GA
    Adv Exp Med Biol; 2023; 1405():405-420. PubMed ID: 37452947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma.
    Inda MM; Muñoz J; Coullin P; Fauvet D; Danglot G; Tuñón T; Bernheim A; Castresana JS
    Histopathology; 2006 Apr; 48(5):579-87. PubMed ID: 16623784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.